Key result
Patient-derived iPSC-VSMCs enable advanced disease modeling, drug screening, and vascular tissue engineering.
Answers are grounded in this paper and cite their sources.
Review summarizes signaling networks and regulators in generating smooth muscle cells for vascular disease modeling.
The developmental origin of vascular smooth muscle cells (VSMCs) has been increasingly recognized as a major determinant for regional susceptibility or resistance to vascular diseases. As a human material-based complement to animal models and human primary cultures, patient induced pluripotent stem cell iPSC-derived VSMCs have been leveraged to conduct basic research and develop therapeutic applications in vascular diseases. However, iPSC-VSMCs (induced pluripotent stem cell VSMCs) derived by most existing induction protocols are heterogeneous in developmental origins. In this review, we summarize signaling networks that govern in vivo cell fate decisions and in vitro derivation of distinct VSMC progenitors, as well as key regulators that terminally specify lineage-specific VSMCs. We then highlight the significance of leveraging patient-derived iPSC-VSMCs for vascular disease modeling, drug discovery, and vascular tissue engineering and discuss several obstacles that need to be circumvented to fully unleash the potential of induced pluripotent stem cells for precision vascular medicine.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2021) conducted a review in Vascular diseases. Patient-derived induced pluripotent stem cell-derived vascular smooth muscle cells (iPSC-VSMCs) was evaluated. Patient-derived iPSC-VSMCs are reviewed regarding signaling networks for lineage-specific derivation and applications in vascular disease modeling, drug discovery, and tissue engineering.
Synapse has enriched 10 related papers. Consider them for comparative context: